At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 120 enrolled
Drug / intervention
Inactivated Influenza Vaccine (2009 / 2010 formulation)biological
Likely dose
Inactivated Influenza Vaccine (2009 / 2010 formulation) 0.5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2009/2010 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged ≥ 18 to < 60 Years) and 'Older Adults' (Aged ≥ 60 Years).
In Brief
A Phase 4 clinical trial evaluating Inactivated Influenza Vaccine (2009 / 2010 formulation) for Influenza. Completed, enrolled 120 participants across 1 site.
Detailed Summary
The purpose of the study is to assess the efficacy and safety of CSL's 2009/2010 formulation of the Enzira vaccine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartMay 2009
Primary CompletionMay 2009
TodayJul 2026
First PostedApr 27, 2009
Enrollment StartMay 1, 2009
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.2 years ago
Interventions
Inactivated Influenza Vaccine (2009 / 2010 formulation)biological
A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.